Condition 1: Nonalcoholic fatty liver disease. Condition 2: Helicobacter pylori infection. Fatty (change of) liver, not elsewhere classified Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Case group: treatment of Helicobacter Pylori with omeprazole (20 mg bid), amoxicilin (1gr bid), and clarithromycin (500 mg bid) orally for 2 weeks. Intervention 2: Control group: will
for example digestive tablet if complained from indigestion. Treatment of helicobacter pylori will be postponed until the end of the study (if the patients provide informed consent).
Treatment - Drugs
Case group: treatment of Helicobacter Pylori with omeprazole (20 mg bid), amoxicilin (1gr bid), and clarithromycin (500 mg bid) orally for 2 weeks.
Control group: will receive only symptomatic therapy, if indicated
Sponsors
research department of medical college of QUMS
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Helicobacter Pylori Infection according to serologic test; Non-alcoholic fatty liver disease according to liver function tests and sonography; consent to participation in the study. Exclusion criteria: presence of any other medical disease; history of hypersensitivity to the prescribed drugs; non-consent to the participation to the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aspartate aminotransferase. Timepoint: at the start and end of the study. Method of measurement: by clinical labratory.;Alanine aminotransferase. Timepoint: at the start and end of the study. Method of measurement: by clinical labratory.;Sonographic indices of fatty liver disease. Timepoint: at the start and end of the study. Method of measurement: by a trained sonologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElahe Hajinourmohammadi
Qazvin University of Medica Sciences
Outcome results
None listed